Citigroup Maintains Neutral on Phibro Animal Health, Lowers Price Target to $44

Benzinga Newsdesk www.benzinga.com Negative 48.0%

Neg 48% Neu 0% Pos 0%

Citigroup analyst Daniel Grosslight maintains Phibro Animal Health (NASDAQ:PAHC) with a Neutral and lowers the price target from $62 to $44.